ALGS Aligos Therapeutics, Inc.
Healthcare$5.74-0.35%ClosedMarket Cap: $35.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.89
P/S
7.58
EV/EBITDA
-0.10
DCF Value
$0.08
FCF Yield
-239.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.0%
Operating Margin
-2033.4%
Net Margin
-1919.7%
ROE
-139.5%
ROA
-139.9%
ROIC
-212.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $2.8M | 100.0% | $-26.9M | $-23.0M | $— | — |
| Q4 null | $169.0K | -52.1% | $-21.8M | $-19.9M | $— | — |
| FY null | $2.2M | 57.5% | $-88.0M | $-24.2M | $— | — |
| Q3 null | $741.0K | 100.0% | $-28.4M | $-31.5M | $— | — |
| Q2 null | $965.0K | 73.2% | $-18.6M | $-15.9M | $— | — |
| Q1 null | $311.0K | 100.0% | $-19.2M | $43.1M | $— | — |
| Q4 null | $629.0K | 100.0% | $-20.6M | $-82.2M | $— | — |
| FY null | $3.9M | 100.0% | $-89.2M | $-131.2M | $— | — |
| Q3 null | $1.3M | 100.0% | $-20.1M | $-19.3M | $— | — |
| Q2 null | $1.1M | 42.5% | $-26.4M | $5.1M | $— | — |
| Q1 null | $986.0K | 100.0% | $-22.0M | $-34.9M | $— | — |
| Q4 2023 | $2.7M | 100.0% | $-26.0M | $-27.9M | $-1.12 | — |